JP2013518603A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518603A5
JP2013518603A5 JP2012552931A JP2012552931A JP2013518603A5 JP 2013518603 A5 JP2013518603 A5 JP 2013518603A5 JP 2012552931 A JP2012552931 A JP 2012552931A JP 2012552931 A JP2012552931 A JP 2012552931A JP 2013518603 A5 JP2013518603 A5 JP 2013518603A5
Authority
JP
Japan
Prior art keywords
chemically modified
modified oligonucleotide
substituted
independently
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012552931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518603A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/024099 external-priority patent/WO2011097641A1/en
Publication of JP2013518603A publication Critical patent/JP2013518603A/ja
Publication of JP2013518603A5 publication Critical patent/JP2013518603A5/ja
Pending legal-status Critical Current

Links

JP2012552931A 2010-02-08 2011-02-08 反復伸張に関連する疾患または病態の治療に有用な方法および組成物 Pending JP2013518603A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30245410P 2010-02-08 2010-02-08
US30245010P 2010-02-08 2010-02-08
US61/302,450 2010-02-08
US61/302,454 2010-02-08
US40515710P 2010-10-20 2010-10-20
US61/405,157 2010-10-20
PCT/US2011/024099 WO2011097641A1 (en) 2010-02-08 2011-02-08 Methods and compositions useful in treatment of diseases or conditions related to repeat expansion

Publications (2)

Publication Number Publication Date
JP2013518603A JP2013518603A (ja) 2013-05-23
JP2013518603A5 true JP2013518603A5 (enExample) 2014-03-20

Family

ID=44355844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552931A Pending JP2013518603A (ja) 2010-02-08 2011-02-08 反復伸張に関連する疾患または病態の治療に有用な方法および組成物

Country Status (4)

Country Link
US (1) US20130059902A1 (enExample)
EP (1) EP2536738A4 (enExample)
JP (1) JP2013518603A (enExample)
WO (1) WO2011097641A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3489360A3 (en) * 2010-07-19 2019-08-28 Ionis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US8569254B2 (en) * 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
CA2833223A1 (en) * 2011-04-22 2012-10-26 Prosensa Technologies B.V. New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP3330278A1 (en) * 2012-02-08 2018-06-06 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
EP3604536B1 (en) 2012-04-23 2024-05-29 Vico Therapeutics B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
EA201492121A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов гемоглобина
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10029916B2 (en) 2012-06-22 2018-07-24 C3Nano Inc. Metal nanowire networks and transparent conductive material
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
US9605255B2 (en) 2012-07-12 2017-03-28 Proqr Therapeutics Ii B.V. Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell
US10020807B2 (en) 2013-02-26 2018-07-10 C3Nano Inc. Fused metal nanostructured networks, fusing solutions with reducing agents and methods for forming metal networks
ES2787600T3 (es) * 2013-07-02 2020-10-16 Ionis Pharmaceuticals Inc Moduladores del receptor de la hormona del crecimiento
WO2015017675A2 (en) * 2013-07-31 2015-02-05 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
CN116970607A (zh) 2014-03-19 2023-10-31 Ionis制药公司 用于调节共济失调蛋白2表达的组合物
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
AU2015252841B2 (en) 2014-05-01 2020-03-19 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
CR20170544A (es) 2015-05-29 2018-03-20 Univ Nat Yang Ming Agentes nucleosidos para la reducción de la actividad perjudicial de los genes que contienen repeticiones de nucleótidos extendidas.
JP6786591B2 (ja) * 2015-08-14 2020-11-18 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 有機エレクトロルミネッセンス素子のためのフェノキサジン誘導体
KR20220100719A (ko) 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
CA3006015A1 (en) 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
US20180028554A1 (en) 2016-07-05 2018-02-01 Biomarin Technologies B.V. Oligomers Having Bicyclic Scaffold Moeities
JOP20190104A1 (ar) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
MX2019005671A (es) 2016-11-16 2020-07-20 Academisch Ziekenhuis Leiden Sustancias para direccionar diversos organos o tejidos seleccionados.
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11268093B2 (en) 2017-01-03 2022-03-08 Rula Zain-Luqman Therapeutic method for huntington's disease
EP3592365A4 (en) * 2017-03-10 2021-01-13 The Board Of Regents Of The University Of Texas System TREATMENT FOR FOX ENDOTHAL CORNEAL DYSTROPHY
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
CA3106986A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
IL326747A (en) 2018-11-02 2026-04-01 Biomarin Tech Bv Bispecific antisense oligonucleotides for dystrophin exon skipping
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
EP4051280A1 (en) 2019-11-01 2022-09-07 Novartis AG The use of a splicing modulator for a treatment slowing progression of huntington's disease
AR123640A1 (es) 2020-09-30 2022-12-28 Biomarin Tech Bv Oligonucleótido
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
WO2026077951A1 (en) 2024-10-07 2026-04-16 Vico Therapeutics B.V. Improved aon for rna editing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2455424A1 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
WO2004101787A1 (ja) * 2003-05-14 2004-11-25 Japan Science And Technology Agency ハンチンチン遺伝子の発現抑制
SI2161038T1 (sl) * 2006-01-26 2014-05-30 Isis Pharmaceuticals, Inc. Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US7569686B1 (en) * 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP6047270B2 (ja) * 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
CA2732343C (en) * 2008-07-29 2017-05-09 The Board Of Regents Of The University Of Texas System Selective inhibition of polyglutamine protein expression
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010048585A2 (en) * 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
GB0821457D0 (en) * 2008-11-24 2008-12-31 Trillion Genomics Ltd Oligonucleotides

Similar Documents

Publication Publication Date Title
AU2024266799A1 (en) Compositions and methods for modulating hbv and ttr expression
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP6542662B2 (ja) オリゴヌクレオチドアナログのボロン酸結合体
TW202016301A (zh) 肝外遞送技術
JP2016533717A5 (enExample)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
AU2017357760A1 (en) Compounds and methods for reducing ATXN3 expression
JP2019525918A5 (enExample)
CA3037042A1 (en) Modified oligonucleotides and methods of use
JP2024543214A (ja) Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置
JP2024545052A (ja) 修飾骨格化学を有するスプライススイッチャーアンチセンスオリゴヌクレオチド
Prakash et al. Evaluation of the effect of 2′-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
EP4396351A1 (en) Compounds and methods for reducing dmpk expression
TW202020152A (zh) 調節rtel1表現之寡核苷酸
WO2022211129A1 (ja) Ａｔｎ１のアンチセンスオリゴヌクレオチド誘導体
JP6826984B2 (ja) アシル−アミノ−ｌｎａオリゴヌクレオチドおよび／またはヒドロカルビル−アミノ−ｌｎａオリゴヌクレオチド
WO2023102548A1 (en) Treatment of neurological diseases using modulators of kcnq2 gene transcripts
KR20250120380A (ko) 안티센스 RNA(asRNA) 기술 및 이의 용도
WO2024257861A1 (ja) 脂質結合オリゴヌクレオチド又はその複合体
RU2024129253A (ru) КОМПОЗИЦИИ SNCA-НАПРАВЛЕННЫХ миРНК ДЛЯ ЛЕЧЕНИЯ SNCA-АССОЦИИРОВАННОГО ЗАБОЛЕВАНИЯ
HK40121031A (zh) 具有经修饰的主链化学的剪接转换器反义寡核苷酸
WO2026080323A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
KR20250116748A (ko) 유전자 침묵 기술로서 산재된 데옥시리보뉴클레오타이드를 갖는 비대칭 짧은 이중체 rna 및 이의 용도